Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Coutre, Steven, Choi, Michael, Furman, Richard R., Eradat, Herbert, Heffner, Leonard, Jones, Jeffrey A., Chyla, Brenda, Zhou, Lang, Agarwal, Suresh, Waskiewicz, Tina, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Wierda, William G., Davids, Matthew S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials And Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922273/
https://ncbi.nlm.nih.gov/pubmed/29305552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-788133
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados